argenx

argenx ARGNF Stock

$965.00   0.000000%
Add to favorites
Market Cap
$60.69B
LOW - HIGH [24H]
$995.00 - $995.00
VOLUME [24H]
$49.00
P/E Ratio
33.42
Earnings per share
$28.87
ISIN
NL0010832176
Price   Prediction

argenx Price Chart

Sorry, that's all we've gotfor now...

argenx (ARGNF) stock price today is 965 USD on OTC Markets OTCPK (0% on the day). Updated .

argenx ARGNF Financial and Trading Overview

argenx stock price 965 USD
Previous Close 965 USD
Open 995 USD
Bid 895.5 USD x 100
Ask 993 USD x 100
Day's Range 995 - 995 USD
52 Week Range 712.03 - 1020 USD
Volume 49 USD
Avg. Volume 15 USD
Market Cap 60.69B USD
Beta (5Y Monthly) -0.064
PE Ratio (TTM) 33.4257
EPS (TTM) 28.87 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est N/A

ARGNF Valuation Measures

Enterprise Value 55.21B USD
Trailing P/E 33.4257
Forward P/E N/A
PEG Ratio (5 yr expected) 1.31
Price/Sales (ttm) 10.258706
Price/Book (mrq) 7.169924
Enterprise Value/Revenue 9.334
Enterprise Value/EBITDA 29.043

Trading Information

argenx Stock Price History

Beta (5Y Monthly) -0.064
52-Week Change 10.91%
S&P500 52-Week Change 8.67%
52 Week High 1020 USD
52 Week Low 712.03 USD
50-Day Moving Average 914.21 USD
200-Day Moving Average 865.73 USD

ARGNF Share Statistics

Avg. Volume (3 month) 15 USD
Avg. Daily Volume (10-Days) 53 USD
Shares Outstanding 62.89M
Float 62.43M
Short Ratio N/A
% Held by Insiders 0%
% Held by Institutions 49.28%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 31.73%
Operating Margin (ttm) 31.94%
Gross Margin 59.83%
EBITDA Margin 32.13%

Management Effectiveness

Return on Assets (ttm) N/A
Return on Equity (ttm) N/A

Income Statement

Revenue (ttm) 5.92B USD
Revenue Per Share (ttm) 95.09 USD
Quarterly Revenue Growth (yoy) 52.10%
Gross Profit (ttm) 3.54B USD
EBITDA 1.9B USD
Net Income Avi to Common (ttm) 1.88B USD
Diluted EPS (ttm) 28.87
Quarterly Earnings Growth (yoy) 47.00%

Balance Sheet

Total Cash (mrq) 5.18B USD
Total Cash Per Share (mrq) 82.89 USD
Total Debt (mrq) 47M USD
Total Debt/Equity (mrq) 0.56 USD
Current Ratio (mrq) N/A
Book Value Per Share (mrq) 134.59

Cash Flow Statement

Operating Cash Flow (ttm) N/A
Levered Free Cash Flow (ttm) N/A

Profile of argenx

Country United States
State N/A
City Amsterdam
Address Laarderhoogtweg 25
ZIP 1101 EB
Phone 31 10 703 8441
Website https://argenx.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 1863

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Q&A For argenx Stock

What is a current ARGNF stock price?

argenx ARGNF stock price today per share is 965 USD.

How to purchase argenx stock?

You can buy ARGNF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for argenx?

The stock symbol or ticker of argenx is ARGNF.

Which industry does the argenx company belong to?

The argenx industry is Biotechnology.

How many shares does argenx have in circulation?

The max supply of argenx shares is 62.89M.

What is argenx Price to Earnings Ratio (PE Ratio)?

argenx PE Ratio is 33.42570000 now.

What was argenx earnings per share over the trailing 12 months (TTM)?

argenx EPS is 28.87 USD over the trailing 12 months.

Which sector does the argenx company belong to?

The argenx sector is Healthcare.

$2.07T
Total marketcap
$68.46B
Total volume
BTC 58.81%   •   ETH 10.04%
Dominance
Select currency